Document › Details
Expression Pathology Inc.. (11/17/09). "Press Release: Liquid Tissue Patent Licensed for Amyloidosis Proteomic Assay. Expression Pathology’s Method Enables Mass Spec Analysis of Amyloid Proteins in Microdissected FFPE Tissue". Rockville, MD.
|Organisation 2||Expression Pathology Inc. (EPI)|
|Today||OncoPlex Diagnostics (OncoPlexDx)|
|Group||OncoPlex Diagnostics (OncoPlexDx)|
|Product||Liquid Tissue® technology (Expression Pathology)|
|Product 2||mass spectrometry services (MS services)|
|Person||Eitner, Casey (Expression Pathology 200806 CEO)|
|Person 2||Tunon, Peter (Expression Pathology 200501– VP Sales + Marketing)|
Expression Pathology, a leader in tissue proteomic analysis, today announced Mayo Clinic has licensed non-exclusive rights to Expression Pathology’s Liquid Tissue® patent for use in diagnosis of systemic amyloidosis in formalin-fixed tissue.
Patented Liquid Tissue® methodology enables solubilization of proteins for mass spectrometric analysis of formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of preserved patient tissue used in clinical pathology testing worldwide. Mayo Clinic has applied the technology to develop a specific and sensitive mass spectrometry based method for diagnosis and classification of amyloidosis in routine biopsy specimens, in a format that is rapid and readily applicable in a clinical setting. This test is being offered to patients worldwide through Mayo Medical Laboratories, Mayo Clinic’s reference laboratory.
With 50,000 diagnosed cases every year worldwide amyloidosis can be a localized or systemic disease, characterized by organ function impairment, sometimes as severe as cardiac and/or renal failure. Subtyping of cases is critical as management of the disease differs radically, from drug therapies to major organ transplants.
The new Liquid Tissue-based method aids in treatment decisions as it exhibits greater sensitivity and specificity than the traditional IHC based classification. In an early case study of 56 FFPE cardiac biopsies involving amyloidosis immunohistochemistry was diagnostic in 19/52 cases and equivocal in 33/52 cases (4 cases no IHC). The mass spectrometry-based Liquid Tissue method identified the amyloidosis type in 53 of 56 cases studied.
“Detailed mass spectrometry analysis of proteins related to specific disease conditions in FFPE tissue is opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions” said Casey Eitner, President and CEO of Expression Pathology. “We are delighted that Mayo Clinic has applied our Liquid Tissue® methodology to solve a difficult medical problem.”
Financial terms of the agreement were not disclosed.
About Mayo Medical Laboratories
Mayo Clinic offers proven diagnostic tests to more than 5,000 health care institutions around the world through Mayo Medical Laboratories, Mayo Clinic’s reference laboratory. Revenue from Mayo Medical Laboratories’ testing is used to support medical education and research at Mayo Clinic. www.MayoMedicalLaboratories.com
About Expression Pathology Inc.
Expression Pathology Inc., Rockville, MD, has developed proprietary techniques for discovery and quantitative analysis of protein biomarkers in FFPE tissue. The company’s Director® laser microdissection slides enable precise, rapid, automated collection of specific cellular features from tumor tissue. Its Liquid Tissue® reagents and technology make possible discovery and measurement of proteins in FFPE tissue by mass spectrometry. EPI employs its Liquid Tissue® proteomics platform in its own and collaborative assay development and biomarker discovery programs, and offers contract research services and products. For more information, please visit www.expressionpathology.com.
Expression Pathology contact:
VP Sales and Marketing
Expression Pathology Inc.
9620 Medical Center Drive
Rockville, MD 20850
Record changed: 2016-03-19
More documents for Mayo Clinic
-  Tefferi, Ayalew, et al.. (7/23/15). “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs [online version]”. Mayo Clinic Proceedings, , pp. ....
-  Hansel, Jeff [The Post-Bulletin]. (3/21/14). "News: Mayo Medical Laboratories Loses Contract, Might Never Get It Back". Rochester, MN....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]